(Reuters) -Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion, the latest in a series of deals U.S. drugmakers have ...

Under terms of the deal, Merck will gain global rights ... The drug is currently in a Phase II clinical trial in China. 1 “Elevated blood concentrations of Lp(a) provides a well-documented risk factor ...

that was reportedly also involved in negotiations to buy out the company. If approved, it would become a companion to Merck's Bayer-partnered heart failure drug Verquvo (vericiguat), cleared by ...

Under the agreement, Hengrui Pharma has granted Merck exclusive rights to develop ... risk factor for atherosclerotic cardiovascular disease, affecting as many as one in five adults globally ...

With the CSF-1R inhibitor space heating up, Merck KGaA ... license to the drug. The German pharma originally paid $70 million for the greater China commercialization rights back in 2023, while ...

Merck will partner with Chinese biotech Abbisko Therapeutics to market and sell the bone-tumor treatment pimicotinib globally, expanding its commercialization rights for the drug beyond Asia.

Experimental Lilly Drug Cuts Genetic Heart Disease Risk Factor by 94% in Trial ... in clinical trials. Merck last week signed a licensing agreement with Jiangsu Hengrui Pharmaceuticals to test ...

Under the latest deal, announced on Tuesday, Merck will get exclusive rights to develop, manufacture and sell Jiangsu Hengrui Pharmaceuticals' experimental oral heart disease drug, HRS-5346 ...

Under the latest deal, announced on Tuesday, Merck will get exclusive rights to develop, manufacture and sell Jiangsu Hengrui Pharmaceuticals' experimental oral heart disease drug, HRS-5346, worldwide ...